Literature DB >> 25836317

Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine.

J B Bier1, A S Finger2, B A Bier3, T A Johnson4, M G Coyle5.   

Abstract

OBJECTIVE: To compare early growth and developmental outcome of infants with in-utero exposure to low-dose methadone (<100 mg per  day), high-dose methadone (⩾100 mg  per day) and buprenorphine. STUDY
DESIGN: A retrospective review of infants with in-utero methadone and buprenorphine exposure who were evaluated at the Southcoast Developmental Pediatric clinic in New Bedford, MA, USA was completed. Growth data and developmental testing results during infancy were compared among the groups. RESULT: Infants in the high-dose methadone group had lower head circumference z scores and a lower mean score on the Alberta Infant Motor Scale (AIMS). Regression results confirmed an association between methadone dose and head circumference z score and AIMS score.
CONCLUSION: Exposure to maternal methadone dose in excess of 100 mg is associated with a reduction in infant head circumference when compared with buprenorphine or lower dose methadone, and may have a negative impact on motor skill development during early infancy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25836317     DOI: 10.1038/jp.2015.22

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  15 in total

1.  High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.

Authors:  John J McCarthy; Martin H Leamon; Michael S Parr; Barbara Anania
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

2.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Authors:  Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

3.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

Authors:  Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis
Journal:  JAMA       Date:  2012-04-30       Impact factor: 56.272

4.  Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.

Authors:  Gabrielle K Welle-Strand; Svetlana Skurtveit; Hendreé E Jones; Helge Waal; Brittelise Bakstad; Lisa Bjarkø; Edle Ravndal
Journal:  Drug Alcohol Depend       Date:  2012-07-25       Impact factor: 4.492

5.  Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications.

Authors:  G S Wilson; M M Desmond; R B Wait
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

6.  Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Authors:  Tim F Oberlander; Shaila Misri; Colleen E Fitzgerald; Xanthoula Kostaras; Dan Rurak; Wayne Riggs
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

7.  Neurodevelopmental and school performance of very low-birth-weight infants: a seven-year longitudinal study.

Authors:  B R Vohr; C T Garcia Coll
Journal:  Pediatrics       Date:  1985-09       Impact factor: 7.124

8.  Visual evoked potentials in infants exposed to methadone in utero.

Authors:  L McGlone; H Mactier; R Hamilton; M S Bradnam; R Boulton; W Borland; M Hepburn; D L McCulloch
Journal:  Arch Dis Child       Date:  2008-02-27       Impact factor: 3.791

9.  Prenatal opiate exposure impairs radial arm maze performance and reduces levels of BDNF precursor following training.

Authors:  Lisa M Schrott; La 'Tonya M Franklin; Peter A Serrano
Journal:  Brain Res       Date:  2008-01-18       Impact factor: 3.252

Review 10.  Developmental outcome of children born to methadone maintained women: a review of longitudinal studies.

Authors:  K Kaltenbach; L P Finnegan
Journal:  Neurobehav Toxicol Teratol       Date:  1984 Jul-Aug
View more
  8 in total

1.  Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.

Authors:  Ludmila N Bakhireva; Bradley D Holbrook; Shikhar Shrestha; Yuridia Leyva; Malia Ashley; Sandra Cano; Jean Lowe; Julia M Stephen; Lawrence Leeman
Journal:  Early Hum Dev       Date:  2018-12-13       Impact factor: 2.079

2.  Psychological Functioning of Women Taking Illicit Drugs during Pregnancy and the Growth and Development of Their Offspring in Early Childhood.

Authors:  Dana Serino Ma; Bradley S Peterson Md; Tove S Rosen Md
Journal:  J Dual Diagn       Date:  2018-09-05

3.  Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.

Authors:  Karol Kaltenbach; Kevin E O'Grady; Sarah H Heil; Amy L Salisbury; Mara G Coyle; Gabriele Fischer; Peter R Martin; Susan Stine; Hendrée E Jones
Journal:  Drug Alcohol Depend       Date:  2018-02-01       Impact factor: 4.492

Review 4.  Neuroimaging in infants with prenatal opioid exposure: Current evidence, recent developments and targets for future research.

Authors:  Rupa Radhakrishnan; Gregory Grecco; Kellen Stolze; Brady Atwood; Samuel G Jennings; Izlin Z Lien; Andrew J Saykin; Senthilkumar Sadhasivam
Journal:  J Neuroradiol       Date:  2020-10-13       Impact factor: 3.447

Review 5.  Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities.

Authors:  Elisabeth Conradt; Tess Flannery; Judy L Aschner; Robert D Annett; Lisa A Croen; Cristiane S Duarte; Alexander M Friedman; Constance Guille; Monique M Hedderson; Julie A Hofheimer; Miranda R Jones; Christine Ladd-Acosta; Monica McGrath; Angela Moreland; Jenae M Neiderhiser; Ruby H N Nguyen; Jonathan Posner; Judith L Ross; David A Savitz; Steven J Ondersma; Barry M Lester
Journal:  Pediatrics       Date:  2019-09       Impact factor: 9.703

6.  Using buprenorphine to treat neonatal abstinence syndrome: a quality improvement study.

Authors:  Sagar Bhandary; Tinisha Lambeth; Amy Holmes; Mary Pylipow
Journal:  J Perinatol       Date:  2021-03-23       Impact factor: 3.225

7.  Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis.

Authors:  Victoria J Monnelly; Ruth Hamilton; Francesca M Chappell; Helen Mactier; James P Boardman
Journal:  Dev Med Child Neurol       Date:  2018-12-03       Impact factor: 5.449

8.  Resting state functional MRI in infants with prenatal opioid exposure-a pilot study.

Authors:  Rupa Radhakrishnan; Nahla M H Elsaid; Senthilkumar Sadhasivam; Thomas A Reher; Abbey C Hines; Karmen K Yoder; Andrew J Saykin; Yu-Chien Wu
Journal:  Neuroradiology       Date:  2020-09-26       Impact factor: 2.995

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.